Clicky

TaiMed Biologics(4147)

Description: TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.


Keywords: Biotechnology Biopharmaceutical Life Sciences Drugs Infectious Diseases Infection Monoclonal Antibodies Monoclonal Antibody Therapy Treatment Of Hiv Humanized Antibody Intravenous Infusion Prevention Of Infectious Diseases Hiv Infections Ibalizumab

Home Page: www.taimedbiologics.com

No. 607, Ruiguang Road
Taipei, 11492
Taiwan
Phone: 886 2 2658 0058


Officers

Name Title
Mr. Chin-Ming Chang Ph.D. Pres & CEO
Dr. David D. Ho M.D. Scientific Co-Founder, Chief Scientific Advisor and Board Director
Dr. Ing-Wen Tsai Ph.D. Co-Founder
Dr. Lan-Bo Chen Ph.D. Co-Founder
Mr. Jack Chen CFO & Chief of Corp. Governance
Hui Fang Zheng Head of Audit Department

Exchange: TWO

Country: TW

Currency: New Taiwan Dollar (NT$)

Forward PE: 263.1579
Trailing PE: 0
Price-to-Book MRQ: 6.4512
Price-to-Sales TTM: 55.9855
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks